厄贝沙坦片联合吲达帕胺片治疗高血压伴心力衰竭的临床研究

Clinical trial of irbesartan tablets combined with indapamide tablets in the treatment of hypertension and heart failure

目的观察厄贝沙坦片联合吲达帕胺片治疗高血压伴心力衰竭的临床疗效及安全性。方法将172例高血压伴心力衰竭患者随机分为对照组和试验组,每组86例。对照组予以厄贝沙坦每次0.15 g,qd,口服;试验组在对照组治疗的基础上,予以吲达帕胺每次2.5 mg,qd,口服。2组患者均治疗2个月。比较2组患者的临床疗效、血压、心功能,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为95.35%(82例/86例)和79.07%(68例/86例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的收缩压分别为(131.45±7.66)和(139.95±6.74)mm Hg,舒张压分别为(84.79±7.54)和(89.86±7.08)mm Hg,左心室收缩末期内径分别为(44.69±5.29)和(53.18±5.94)mm,左心室舒张末期内径分别为(35.09±4.84)和(41.28±5.69)mm,左心室射血分数分别为(52.19±6.06)%和(44.62±5.35)%,6 min步行距离分别为(301.87±34.25)和(192.78±22.64)m,差异均有统计学意义(均P<0.05)。2组患者的药物不良反应均以咳嗽、口干、头晕头痛和消化道反应为主。试验组和对照组的总药物不良反应发生率分别为10.47%和12.79%,差异无统计学差异(P>0.05)。结论厄贝沙坦片联合吲达帕胺片治疗高血压伴心力衰竭的临床疗效确切,其能明显控制患者的血压水平,改善心功能,且不增加药物不良反应的发生率。

Objective To observe the clinical efficacy and safety of irbesartan tablets combined with indapamide tablets in the treatment of hypertension and heart failure. Methods A total of 172 patients with hypertension and heart failure were randomly divided into control and treatment groups with 86 cases per group. Control group was treated with irbesartan 0. 15 g per time,qd,orally. Treatment group received indapamide 2. 5 mg per time,qd,orally,on the basis of control group. The two groups were treated for 2 months. The clinical efficacy,blood pressure,cardiac function and adverse drug reactions were compared between two groups. Results After treatment,the total effective rates of treatment and control groups were 95. 35%（ 82 cases/86 cases） and79. 07%（ 68 cases/86 cases） with significant difference（ P 0. 05）.After treatment,the main indexes of treatment and control groups were compared： the systolic blood pressure were（ 131. 45 ± 7. 66） and（ 139. 95 ± 6. 74） mm Hg,the diastolic blood pressure were（ 84. 79 ± 7. 54） and（ 89. 86 ± 7. 08） mm Hg,the left ventricular end systolic diameter were（ 44. 69 ± 5. 29） and（ 53. 18 ± 5. 94） mm,the left ventricular end diastolic diameter were（ 35. 09 ± 4. 84） and（ 41. 28 ± 5. 69） mm,the left ventricular ejection fraction were（ 52. 19 ± 6. 06） and（ 44. 62 ± 5. 35） %,the 6 min walking distance were（ 301. 87 ± 34. 25） and（ 192. 78 ± 22. 64） m,the differences were statistically significant（ all P 0. 05）. The adverse drug reactions of two groups were cough,dry mouth,dizziness,headache and digestive tract reactions. The total incidences of adverse drug reactions in treatment and control groups were 10. 47% and 12. 79% without significant difference（ P 0. 05）. Conclusion Irbesartan tablets combined with indapamide tablets have a definitive clinical efficacy in the treatment of hypertension and heart failure,which can obviously control the blood pressure,improve heart function,without increasing the incidence of adverse drug reactions.